ライフサイエンスコーパス: aspirin

1 (6589 [50%] to ticagrelor and 6610 [50%] to aspirin).

2 n total cancer mortality, among those taking aspirin.

3 an (at doses of 20 mg or 10 mg) or 100 mg of aspirin.

4 r lower-intensity anticoagulation therapy or aspirin.

5 f cardiovascular events than those receiving aspirin.

6 agrelor 60 mg, or placebo on a background of aspirin.

7 alicin, a natural antipyretic that resembles aspirin.

8 ported for fellow analgesics paracetamol and aspirin.

9 e significantly reduced among persons taking aspirin.

10 ), and a delayed-release enteric-coated (EC) aspirin.

11 ar in 1 of every 74 patients who discontinue aspirin.

12 9; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both co

13 n (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.5

14 assess rivaroxaban 2.5 mg twice daily versus aspirin 100 mg daily, in addition to clopidogrel or tica

15 tment with rivaroxaban 2.5 mg twice daily or aspirin 100 mg daily.

16 rivaroxaban (2.5 mg orally twice a day) plus aspirin (100 mg once a day), rivaroxaban alone (5 mg ora

17 e oral rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5

18 ntly higher use of statins (15.9% vs. 9.1%), aspirin (12.7% vs. 8.5%), invasive coronary angiography

19 teroidal anti-inflammatory drugs [NSAIDs] or aspirin, 17 hormones, and 7 lipid-lowering agents).

20 twice daily for days 2-90, given orally) or aspirin (300 mg on day 1 followed by 100 mg daily for da

21 0 to 150 mg/d); 914 (20%) received high-dose aspirin (300 to 600 mg/d), dipyridamole, or other agents

22 single loading dose (ticagrelor 180 mg plus aspirin 325 mg) and as daily/maintenance treatment for 5

23 DHA or placebo capsules enriched with 81 mg aspirin; 46 enrollees completed the trial.

24 erapy (3613 of 4527 [80%]) received low-dose aspirin (50 to 150 mg/d); 914 (20%) received high-dose a

25 e design and synthesis of a novel prodrug of aspirin, [6]-gingerol aspirinate (GAS).

26 of intensive antiplatelet therapy (combined aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 m

27 intenance therapy: ticagrelor 90 mg BID plus aspirin 81 mg QD).

28 nce for a chemopreventive effect of low-dose aspirin against colorectal (and other) cancer.

29 aroxaban alone (5 mg orally twice a day), or aspirin alone (100 mg orally once a day).

30 aspirin reduced mortality when compared with aspirin alone (262 [3%] of 8313 vs 339 [4%] of 8261; HR

31 ted in more major bleeds than treatment with aspirin alone (263 [3%] of 8313 vs 158 [2%] of 8261; HR

32 spirin reduced the primary outcome more than aspirin alone (347 [4%] of 8313 vs 460 [6%] of 8261; haz

33 ry outcome when compared with treatment with aspirin alone (411 [5%] of 8250 vs 460 [6%] of 8261; HR

34 Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite

35 n in the rivaroxaban alone group than in the aspirin alone group (236 [3%] of 8250 vs 158 [2%] of 826

36 n increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504;

37 aroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1.68, 95% CI 1.17-2.40; p=0.0043

38 on of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiova

39 VASc >/=2, 118,398 (40.2%) were treated with aspirin alone, and 176,244 (59.8%) were treated with war

40 death, MI, or stroke compared with low-dose aspirin alone, but at an increased risk of major bleedin

41 d increases bleeding risk in comparison with aspirin alone.

42 alone, and in 61 [1%] patients who received aspirin alone.

43 ovascular and limb events when compared with aspirin alone.

44 ceived ticagrelor with or without aspirin or aspirin alone.

45 eived DAPT and 251 (31.6%) patients received aspirin alone.

46 omes were randomly assigned; 1518 to receive aspirin and 1519 to receive rivaroxaban.

47 Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice

48 r risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor.

49 wth kinetics, whereas combination therapy of aspirin and a PI3K inhibitor further attenuated tumor gr

50 urrently with an antiplatelet drug (low-dose aspirin and a VKA: 3.6% of cases and 1.1% of controls; a

51 The majority of SCAD patients were taking aspirin and beta-blocker therapy at discharge and at fol

52 iation between postdiagnosis use of low-dose aspirin and cancer-specific mortality among patients wit

53 fter coronary stenting-largely consisting of aspirin and clopidogrel and without indication to oral a

54 Patients were treated with aspirin and clopidogrel for the entire year.

55 DAPT (aspirin and clopidogrel) for 24 versus 6 months.

56 nt net benefit in favour of rivaroxaban plus aspirin and deaths were reduced by 23%.

57 prising either clopidogrel alone or combined aspirin and dipyridamole).

58 tion, but had low case fatality in trials of aspirin and is not generally thought to cause long-term

59 We evaluated aspirin and non-aspirin NSAID use and risk of pancreatic

60 f CRC that would benefit the most from using aspirin and other nonsteroidal anti-inflammatory drugs (

61 Our study supports the evaluation of aspirin and PI3K pathway inhibitors as a combination the

62 1% of subjects after administration of plain aspirin and PL2200 (p < 0.0001).

63 pirin; p = 0.30 for comparison between plain aspirin and PL2200).

64 Compared with findings for plain aspirin and PL2200, this high rate of nonresponsiveness

65 Aspirin and statins have a positive impact on these reso

66 low-dose use of two anti-inflammatory drugs, aspirin and triptolide, reduces spontaneous lung cancer

67 non-immune hemolytic anemia upon exposure to aspirin and various antimalarial drugs.

68 usually anticoagulated with a combination of aspirin and vitamin K antagonists.

69 plus aspirin, eligible patients remained on aspirin and were randomly assigned to continued thienopy

70 BACKGROUND & AIMS: Use of aspirin and/or non-aspirin nonsteroidal anti-inflammator

71 irin, PL2200 (a modified-release lipid-based aspirin), and a delayed-release enteric-coated (EC) aspi

72 i-CD41 mAb treatment, platelet inhibition by aspirin, and adoptive transfer of wild-type (WT) platele

73 was associated with greater use of statins, aspirin, and invasive procedures, and higher costs than

74 .34 to 2.17; p = 0.74) were observed between aspirin- and DAPT-treated patients, respectively.

75 Because the effective doses of aspirin are consistent with the inhibition of cyclooxyge

76 Aspirin as secondary prevention may be more justified fr

77 There are limited data on aspirin (ASA) desensitization for patients with coronary

78 ing body of research suggests daily low-dose aspirin (ASA) reduces heart diseases and colorectal canc

79 arlier, treatment with ticagrelor + low-dose aspirin (ASA) reduces the risk of cardiovascular (CV) de

80 oratory analysis, ticagrelor was superior to aspirin at preventing stroke, myocardial infarction, or

81 igh risk for preterm preeclampsia to receive aspirin, at a dose of 150 mg per day, or placebo from 11

82 tion treated with antiplatelet drugs (mainly aspirin based, without routine PPI use) after the event

83 INTERPRETATION: In patients receiving aspirin-based antiplatelet treatment without routine PPI

84 he association of 5 AMI admission therapies (aspirin, beta-blockers, acute reperfusion therapy, door-

85 Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces my

86 inhalation challenge of Ptges(-/-) mice with aspirin blocked IL-33-dependent mast cell activation, me

87 Current use of low-dose aspirin (cases: 26.7%, controls: 22.4%; adjusted OR, 1.2

88 reactions, and after completion of ketorolac/aspirin challenge/desensitization in 12 patients with AE

89 Use of low-dose aspirin, clopidogrel, a vitamin K antagonist (VKA), a di

90 of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of gui

91 ; open label) and to antiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded).

92 The use of the rivaroxaban plus aspirin combination increased major bleeding compared wi

93 py alone (aspirin, warfarin, clopidogrel, or aspirin combined with extended-release dipyridamole; med

94 The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composit

95 sk patients presenting to the ED, the use of aspirin compared with placebo did not reduce the risk of

96 Such AuNR@G-P-aspirin complexes were used for near-infrared laser-trig

97 e of anti-inflammatory medications (statins, aspirin, corticosteroids, and nonsteroidal anti-inflamma

98 t 10 years, and are willing to take low-dose aspirin daily for at least 10 years." This recommendatio

99 Aspirin decreased viability and anchorage-independent gr

100 The exact mechanisms of aspirin desensitization are not clearly understood.

101 Two hundred seventy-five patients underwent aspirin desensitization at Scripps Clinic between Januar

102 Aspirin desensitization is an effective treatment option

103 aluate the safety and outcomes of outpatient aspirin desensitization procedures.

104 Aspirin desensitization protocol modifications have impr

105 Most patients undergoing aspirin desensitization will have symptoms.

106 ting that it does not block reactions during aspirin desensitization.

107 that might predict reaction severity during aspirin desensitization.

108 While aspirin directly inhibits IkappaB kinases (IKKs) to phos

109 We investigated whether long-term low-dose aspirin discontinuation and treatment gaps increase the

110 reasing concerns about risks associated with aspirin discontinuation in the absence of major surgery

111 r TXB2 >3.1 ng/ml) within 72 h after 3 daily aspirin doses.

112 Randomized patients with available aspirin dosing information in COGENT (N = 3,752) were di

113 tors have mostly been studied in addition to aspirin; dual-antiplatelet therapy proved superiority co

114 is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm pre

115 Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet b

116 ic respiratory inflammation and reactions to aspirin, each involving the marked overproduction of cys

117 ienopyridine (clopidogrel or prasugrel) plus aspirin, eligible patients remained on aspirin and were

118 ather than warfarin and avoiding concomitant aspirin, especially in patients of older age.

119 Aspirin-exacerbated respiratory disease (AERD) is charac

120 Aspirin-exacerbated respiratory disease (AERD) is charac

121 lated in several diseases, including asthma, aspirin-exacerbated respiratory disease (AERD), inflamma

122 inosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respiratory disease (AERD).

123 duced respiratory reactions in patients with aspirin-exacerbated respiratory disease (AERD).

124 lls from the nasal polyps of 3 patients with aspirin-exacerbated respiratory disease by using fluores

125 Aspirin-exacerbated respiratory disease is a severe form

126 Aspirin-exacerbated respiratory disease, a severe asthma

127 ded group 2 innate lymphoid cells (ILC2s) in aspirin-exacerbated respiratory disease-like Ptges(-/-)

128 ization is an effective treatment option for aspirin-exacerbated respiratory disease.

129 hould be made available to all patients with aspirin-exacerbated respiratory disease.

130 Aspirin exerts antiplatelet effects through irreversible

131 high proportion of patients treated with EC aspirin failed to achieve complete inhibition of TXB2 ge

132 Low-dose aspirin for cancer prevention is often cited as the most

133 r phenprocoumon or dabigatran in addition to aspirin for long-term anticoagulation.

134 atients with chronic gastritis who had taken aspirin for more than 3 years.

135 a cohort study of 601 527 users of low-dose aspirin for primary or secondary prevention in the Swedi

136 ticle reviews the literature on the topic of aspirin for primary prevention in general, and in subjec

137 Preventive Services Task Force endorsed aspirin for primary prevention of cardiovascular disease

138 it to a 57-year-old man considering starting aspirin for primary prevention.

139 rompted trials comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis

140 Patients were exposed to three 325-mg aspirin formulations: plain aspirin, PL2200 (a modified-

141 days compared with 350 (6.9%) of 5071 in the aspirin group (0.97 [0.84-1.13]; p=0.72).

142 ollow up, which left 798 participants in the aspirin group and 822 in the placebo group.

143 39 patients with ipsilateral stenosis in the aspirin group had an occurrence of stroke, myocardial in

144 .3%) in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.

145 ia occurred in 13 participants (1.6%) in the aspirin group, as compared with 35 (4.3%) in the placebo

146 is in the ticagrelor group compared with the aspirin group.

147 eiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor

148 dose" (</= 100 mg) and "high-dose" (>100 mg) aspirin groups.

149 Patients who discontinued aspirin had a higher rate of cardiovascular events than

150 DHA + aspirin had no significant effect on individual plaque b

151 Thus, addition of rivaroxaban to aspirin has the potential to substantially reduce morbid

152 l research in trials combining Vitamin D and aspirin have begun as part of such investigation.

153 ed with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspir

154 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients; NCT01515657).

155 blind, controlled trial of ticagrelor versus aspirin in patients aged 40 years or older with a non-ca

156 erol Levels), and CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trials.

157 tic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascula

158 physicians balance the benefits and harms of aspirin in primary disease prevention, the Task Force is

159 long-term users, discontinuation of low-dose aspirin in the absence of major surgery or bleeding was

160 rms may exceed benefits for persons starting aspirin in their 70s and for many during the first 10 to

161 -induced inflammation through the release of aspirin in tumor milieu.

162 Treatment with low-dose aspirin in women at high risk for preterm preeclampsia r

163 f plasma salicylurate, a major metabolite of aspirin, in 396 pancreatic cancer cases and 784 matched

164 ients who received combined rivaroxaban plus aspirin, in 84 [1%] patients who received rivaroxaban al

165 Adverse effects to aspirin included urticaria (n=177, 53.6%), angioedema (n

166 n of NOS2 and COX2 using amino-guanidine and aspirin/indomethacin yielded an additive reduction in th

167 Furthermore, triptolide and aspirin induce distinct mechanisms to potentiate each ot

168 product of mast cells and is an effector of aspirin-induced respiratory reactions in patients with a

169 con and a practical risk-based algorithm for aspirin initiation in daily practice.

170 es have suggested a therapeutic benefit from aspirin intake in cancers harboring oncogenic PIK3CA Her

171 bgroup analysis revealed that female gender, aspirin intolerance and revision FESS were associated wi

172 Purpose Regular use of aspirin is associated with improved survival for patient

173 However, the major limitation to the use of aspirin is its side effect to cause ulceration and bleed

174 Aspirin is recommended for secondary prevention after tr

175 A limitation of aspirin is that some patients, particularly those with d

176 bition of prostaglandin (PG) biosynthesis by aspirin-like drugs.

177 y artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased maj

178 ood lipids, glycemic control, and the use of aspirin) management for the prevention of CVD among pati

179 Lastly, aspirin markedly attenuates glycolysis and cancer stem-l

180 ast cancer cells have greater sensitivity to aspirin-mediated growth suppression than their wild-type

181 tiplatelet treatment for 90 days followed by aspirin monotherapy and intensive management of vascular

182 iving DAPT (aspirin plus thienopyridine) and aspirin monotherapy at 30 days post-operatively.

183 let therapy proved superiority compared with aspirin monotherapy for the prevention of ischemic event

184 antiplatelet therapy reduces VTE risk beyond aspirin monotherapy is unknown.

185 e similar for patients receiving DAPT versus aspirin monotherapy respectively, in subgroups with pre-

186 Compared with aspirin monotherapy, no associated differences were obse

187 significant reduction in recurrent VTE with aspirin monotherapy.

188 alysis including patients on mainly low-dose aspirin, NOACs were found to be more effective (outcome

189 The rate of aspirin nonresponsiveness was 15.8%, 8.1%, and 52.8% for

190 Aspirin nonresponsiveness was defined as a level of resi

191 BACKGROUND & AIMS: Use of aspirin and/or non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) re

192 Aspirin, nonsteroidal antiinflammatory drugs (NSAID), an

193 We evaluated aspirin and non-aspirin NSAID use and risk of pancreatic adenocarcinoma

194 Regular aspirin or non-aspirin NSAID use was not associated with future risk of

195 Use of aspirin or non-aspirin NSAIDs was not associated with pancreatic cancer

196 We evaluated the effects of aspirin on genetic/epigenetic alterations in precancerou

197 A modest effect of DHA + aspirin on Porphyromonas gingivalis counts was associate

198 ischaemic stroke, we studied the effects of aspirin on the risk and severity of recurrent stroke, st

199 5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice

200 Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular

201 Compared with nonusers, postdiagnostic aspirin-only users had more favorable OS (HR, 0.75; 95%

202 patients received ticagrelor with or without aspirin or aspirin alone.

203 in or clopidogrel in patients with so-called aspirin or clopidogrel "resistance."

204 use of laboratory tests to guide the dose of aspirin or clopidogrel in patients with so-called aspiri

205 g was not affected by anticoagulants such as aspirin or heparin.

206 Regular aspirin or non-aspirin NSAID use was not associated with

207 Use of aspirin or non-aspirin NSAIDs was not associated with pa

208 k for perioperative complications to receive aspirin or placebo and tranexamic acid or placebo.

209 dex acute coronary syndromes event to either aspirin or rivaroxaban based on a computer-generated ran

210 e or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) tr

211 thesize the anti-inflammatory prodrug pyrene-aspirin (P-aspirin) with a cleavable ester bond and also

212 ively (p < 0.001 for both comparisons vs. EC aspirin; p = 0.30 for comparison between plain aspirin a

213 relor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).

214 relor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).

215 d extent of serum thromboxane generation and aspirin pharmacokinetics were measured in 40 patients wi

216 Moving from general aspects of aspirin pharmacology and specific issues in diabetes mel

217 to three 325-mg aspirin formulations: plain aspirin, PL2200 (a modified-release lipid-based aspirin)

218 iveness was 15.8%, 8.1%, and 52.8% for plain aspirin, PL2200, and EC aspirin, respectively (p < 0.001

219 e a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (1

220 tiplatelet treatment (aspirin/clopidogrel vs aspirin/placebo; double-blinded).

221 Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events

222 Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithro

223 trial, we compared patients receiving DAPT (aspirin plus thienopyridine) and aspirin monotherapy at

224 Low-dose aspirin prescriptions were identified from linkages to t

225 Rivaroxaban plus aspirin reduced mortality when compared with aspirin alo

226 The combination of rivaroxaban plus aspirin reduced the primary outcome more than aspirin al

227 t ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienop

228 Reduced bioavailability may contribute to "aspirin resistance" in patients with diabetes.

229 antiplatelet therapies: Could the patient be aspirin "resistant" or clopidogrel "resistant"?

230 and 52.8% for plain aspirin, PL2200, and EC aspirin, respectively (p < 0.001 for both comparisons vs

231 ly to report that they are not on statin and aspirin, respectively, had a significantly greater utili

232 iven mouse mammary tumors treated daily with aspirin resulted in decreased tumor growth kinetics, whe

233 atory drugs (RR, 0.77; 95% CI, 0.65-0.92) or aspirin (RR, 0.81; 95% CI, 0.67-0.99), as well as high i

234 However, aspirin's role in cancer prevention is still emerging, a

235 stionnaire, medication use, nasal polyposis, aspirin sensitivity and neutrophil/eosinophil responsive

236 rum of patients, irrespective of the type of aspirin sensitivity manifestation, with indications to u

237 for induction of type 2 immunopathology and aspirin sensitivity.

238 among people with diabetes who regularly use aspirin should be further examined in preclinical and hu

239 s restricted to the subgroups of patients on aspirin therapy (n=21 722) from 4 randomized controlled

240 bleeding was similar with rivaroxaban versus aspirin therapy (total 154 patients [5%]; 80 participant

241 d up for 3 additional months while receiving aspirin therapy alone.

242 omized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report

243 Oral docosahexaenoic acid (DHA) + aspirin therapy has been shown to reduce periodontal pro

244 omized, controlled trial suggests that DHA + aspirin therapy improves periodontitis largely by modula

245 preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure

246 Whether DHA + aspirin therapy influences specific bacterial burden in

247 current atherothrombotic events, which makes aspirin therapy of potential value in these subjects.

248 to evaluate the impact of DHA with low-dose aspirin therapy on periodontal bacterial profile in pati

249 secondary prevention studies suggested that aspirin therapy reduces CRC incidence and perhaps mortal

250 d completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events rema

251 they would balance the benefits and harms of aspirin therapy, and explain how they would incorporate

252 nts with atrial fibrillation and concomitant aspirin therapy, we conducted a systematic review and st

253 valvular atrial fibrillation and concomitant aspirin therapy.

254 s remain when NOACs have to be combined with aspirin therapy.

255 relor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (ticag

256 relor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial,

257 relor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54), in wh

258 relor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction) 54 trial

259 We ascribed the effects of aspirin to AMP-activated protein kinase (AMPK) activatio

260 ROUND & AIMS: Preclinical studies have shown aspirin to have anticancer properties and epidemiologic

261 emic stroke treatment, some aspects of which-aspirin to prevent recurrence, and treating patients in

262 Urinary eicosanoid levels were measured in aspirin-tolerant control subjects and patients with AERD

263 primary composite outcome between DAPT- and aspirin-treated patients (12.6% vs. 16.0%; adjusted haza

264 Similarly, 56% of EC aspirin-treated subjects had serum TXB2 levels >3.1 ng/m

265 changes in P. gingivalis levels in the DHA + aspirin treatment group.

266 Adherence to low-dose aspirin treatment in the absence of major surgery or ble

267 Combined rivaroxaban plus aspirin treatment resulted in more major bleeds than tre

268 e whether systemic preventive treatment with Aspirin-triggered RvD1 (AT-RvD1) reduces inflammation an

269 dent cohorts in the United Kingdom, low-dose aspirin usage was not associated with increased survival

270 without aspirin use (control), AG cases with aspirin use (AG group), and GC cases with aspirin use (G

271 luding atrophic gastritis (AG) cases without aspirin use (control), AG cases with aspirin use (AG gro

272 th aspirin use (AG group), and GC cases with aspirin use (GC group), were analyzed.

273 0.71), especially among those who initiated aspirin use (OS: HR, 0.64; 95% CI, 0.47 to 0.86; CRC-spe

274 s) for cancer-specific mortality by low-dose aspirin use after adjusting for potential confounders.

275 cohorts to determine the association between aspirin use and cancer-specific mortality in patients wi

276 prior stroke/transient ischemic attack, and aspirin use at baseline.

277 , the Task Force issued a guideline titled, "Aspirin Use for the Primary Prevention of Cardiovascular

278 Task Force recommended "initiating low-dose aspirin use for the primary prevention of cardiovascular

279 The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in

280 Regular aspirin use may prevent a substantial proportion of colo

281 Aspirin use was associated with a significant reduction

282 In a pre-planned subgroup analysis, regular aspirin use was associated with reduced pancreatic cance

283 Long-term aspirin use was not associated with cancer-specific mort

284 Duration of aspirin use was not associated with hearing loss (for >6

285 igher risks of hearing loss, but duration of aspirin use was not.

286 es and epidemiologic studies have associated aspirin use with longer survival times of patients with

287 ainment of 5 secondary prevention parameters-aspirin use, lipid control (low-density lipoprotein chol

288 s of heterogeneity (ie, age, BMI, sex, race, aspirin use, omega-3 PUFA levels, or variants of the FAD

289 f hypercholesterolemia, history of diabetes, aspirin use, statin use, blood pressure medication use,

290 In patients with long-term aspirin use, the changes of molecular events in AM but n

291 oking status, educational level, income, and aspirin use.

292 n cancer-specific mortality, were similar in aspirin users vs non-users after diagnosis with esophage

293 Aspirin users were found to be at increased risk for maj

294 l patient data from all randomised trials of aspirin versus control in secondary prevention after TIA

295 group) or to receive medical therapy alone (aspirin, warfarin, clopidogrel, or aspirin combined with

296 this high rate of nonresponsiveness with EC aspirin was associated with lower exposure to acetylsali

297 ondary prevention in arterial thrombosis and aspirin with anticoagulants for primary and secondary pr

298 anti-inflammatory prodrug pyrene-aspirin (P-aspirin) with a cleavable ester bond and also facilitate

299 combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor has not been assesssed i

300 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rate